$HRMY2025 · v5

Harmony Biosciences (HRMY): EV/EBITDA 7.1x and EV/FCF 4.8x Price Durability Risk into a 21.5% Growth, 16.8% FCF Yield Profile

Mixed but researchable candidate

66Signal score
2025Fiscal year
HealthcareSector
66Mixed but researchable candidate
Report date
Friday, 12 June 2026
Company
Harmony Biosciences Holdings, Inc.
Sector
Healthcare
Industry
Biotechnology
Version
v5

Research PDF

signalshield-HRMY-2025-v5.pdf
Download PDF
⬇ Download full PDFDirect download. Opens in any PDF reader. Public archive report.

This report is provided for informational research support only. It does not constitute investment, financial, or trading advice.

← All research reports